Press Releases

Dr. Venkat Manohar, a seasoned veteran in the field of analytical science, is now a part of Diabliss’ exceptional advisory board. Diabliss is in a state of rapid expansion and his inclusion will spearhead the company’s progress in creating low glycemic index foods.

Dr. Manohar has had a remarkable career spanning over 40 years in various multinational companies. His journey began with a Ph.D. in Physics from the University of Madras. He has received several awards for his contributions in analysis across his glorious professional years. He is a member of Method Review Committee of FSSAI and has more than 70 publications and 6 patents to his credit.

San Francisco, California, US, September 9, 2018: Diabliss, the world’s 1st low GI sugar, is proud to announce that it has successfully launched in American retail stores. The sales strategy initially focussed on online sales from Amazon and Amazon Prime where Diabliss was at the top 20% of the new product launch category in terms of product purchases, and consumer views and responses. This was achieved in the very 1st week!

Chennai, Tamil Nadu, India, August 16, 2018 – We are pleased to announce that the International Journal of Diabetes Research, a prestigious American Medical Journal, has published Diabliss’s human clinical studies. The study was titled ‘Diabliss’s effect on blood glucose levels in Type-2 Diabetes Mellitus’ and conducted at Sugaen Life Sciences, AP and Annamalai University, TN.

Diabliss is pleased to welcome Dr Arun Chockalingam to its advisory board. His addition to the board strengthens Diabliss’ resolve to provide innovative low GI products to diabetics. A few of Dr Chockalingam’s honours include being a world renowned public health practitioner and Secretary General of the World Hypertension League.

Dr Chockalingam is passionate about global health research, particularly on non-communicable disease prevention and control in low-and middle-income countries. He has established research collaborations in China, India, Germany, etc.